AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9755357 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term maintenance treatment for recurrent unipolar major depression; specific intervention details not provided.
Number of subjects: 0
Study 9755357 — intervention group
Group type: COMPARATOR
Intervention: Continuation treatment of major depression; specific intervention details not provided.
Number of subjects: 0
Study 7736899 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 16
Study 7736899 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of glucose with model assessment (CIGMA)
Number of subjects: 16
Study 7736899 — intervention group
Group type: COMPARATOR
Intervention: Hyperglycaemic clamp (10 mmol/l)
Number of subjects: 16
Study 2674713 — intervention group
Group type: EXPERIMENTAL
Intervention: Nibbling diet (17 snacks per day)
Number of subjects: 7
Study 2674713 — intervention group
Group type: COMPARATOR
Intervention: Three-meal diet (3 meals per day)
Number of subjects: 7
Study 169104 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 47
Study 169104 — intervention group
Group type: COMPARATOR
Intervention: Aminosidin-polymyxin B combination
Number of subjects: 47
Study 31177183 — intervention group
Group type: EXPERIMENTAL
Intervention: GOP infusion
Number of subjects: 26
Study 31177183 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 26
Study 27053635 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline MRI parameters (T2 lesion number, T1 and T2 lesion volumes, corpus callosum (CC), thalamic fraction)
Number of subjects: 177
Study 27053635 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month MRI parameters (Expanded Disability Status Scale (EDSS), number of new or enlarging T2 lesions, CC volume % change)
Number of subjects: 177
Study 27053635 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite score from best predictors of SDP
Number of subjects: 177
Study 25637266 — intervention group
Group type: EXPERIMENTAL
Intervention: Edivoxetine (EDX) 6 mg or 9 mg once daily for 14 or 15 days
Number of subjects: 40
Study 25637266 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) 80 mg once daily for 14 or 15 days
Number of subjects: 40
Study 25637266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 24102571 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg kg(‐1) over 10 minutes, followed by 0.4 μg kg(‐1)h(‐1) for 60 minutes)
Number of subjects: 35
Study 24102571 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 35
Study 22097636 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitch-only condition
Number of subjects: 61
Study 22097636 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-axis condition (pitch and roll)
Number of subjects: 61
Study 22097636 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-axis condition (pitch, roll, and yaw)
Number of subjects: 61
Study 22097636 — intervention group
Group type: COMPARATOR
Intervention: Control (pitch-only)
Number of subjects: 61
Study 19332208 — intervention group
Group type: EXPERIMENTAL
Intervention: Average inhospital glucose levels (mean of glucose levels at admission, 6 hours, and 24 hours)
Number of subjects: 30536
Study 19332208 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes history
Number of subjects: 30536
Study 19332208 — intervention group
Group type: EXPERIMENTAL
Intervention: Average glucose > or =144 mg/dL (8 mmol/L)
Number of subjects: 30536
Study 19332208 — intervention group
Group type: COMPARATOR
Intervention: Diabetes history alone
Number of subjects: 30536
Study 19332208 — intervention group
Group type: COMPARATOR
Intervention: Average glucose alone
Number of subjects: 30536
Study 19332208 — intervention group
Group type: COMPARATOR
Intervention: Glucose plus diabetes history
Number of subjects: 30536
Study 21797816 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg
Number of subjects: 14
Study 21797816 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 40 mg
Number of subjects: 14
Study 21797816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 21797816 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant (20 or 40 mg)
Number of subjects: 14
Study 15951652 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency facet joint denervation
Number of subjects: 81
Study 15951652 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 81
Study 12730412 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaine (6 g daily for 6 weeks)
Number of subjects: 36
Study 12730412 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (800 micro g daily for 6 weeks)
Number of subjects: 36
Study 12730412 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6 g daily for 6 weeks)
Number of subjects: 36
Study 10473149 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-position grip strength test (5PGST)
Number of subjects: 30
Study 8847950 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan-free amino acid mixture (31.5 grams)
Number of subjects: 6
Study 8847950 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 6
Study 2285608 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy using Flutamide and LHRH agonist (or orchiectomy) for an average of 771 days (24‐2607 days)
Number of subjects: 363
Study 2285608 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy using Flutamide and LHRH agonist (or orchiectomy)
Number of subjects: 363
Study 2285608 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (not specified in detail)
Number of subjects: 363
Study 393731 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg nickel supplements given on Monday and Tuesday of each week for at least 1 month
Number of subjects: 10
Study 393731 — intervention group
Group type: COMPARATOR
Intervention: Dietary restriction of nickel
Number of subjects: 10
Study 28531302 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives for smoking cessation (Contingent, n = 143)
Number of subjects: 253
Study 28531302 — intervention group
Group type: COMPARATOR
Intervention: Control condition (Noncontingent, n = 110)
Number of subjects: 253
Study 28166816 — intervention group
Group type: EXPERIMENTAL
Intervention: ACHRU-CPP program (6-month interprofessional, nurse-led program)
Number of subjects: 160
Study 26063161 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth+CP (n=166)
Number of subjects: 331
Study 26063161 — intervention group
Group type: COMPARATOR
Intervention: standard mHealth (n=165)
Number of subjects: 331
Study 23905242 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified group: preoperative intramuscular injection of 50 mg dolantin, venous injection of 2 ml physiological saline, 10 mg dexamethasone, 5 mg ephedrine
Number of subjects: 118
Study 23905242 — intervention group
Group type: COMPARATOR
Intervention: Traditional group: intramuscular injection of 10 mg diazepam prior to routine anesthesia
Number of subjects: 118
Study 23905242 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified group
Number of subjects: 118
Study 23905242 — intervention group
Group type: COMPARATOR
Intervention: Traditional group
Number of subjects: 118
Study 21084068 — intervention group
Group type: EXPERIMENTAL
Intervention: Safer environmental interventions (nuisance party enforcement, minor decoy operations, DUI checkpoints, social host ordinances, media visibility)
Number of subjects: 14000
Study 21084068 — intervention group
Group type: EXPERIMENTAL
Intervention: Safer environmental interventions
Number of subjects: 14000
Study 18758699 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (starting dose 2.5 mg once daily for 6 weeks)
Number of subjects: 39
Study 18758699 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (starting dose 25 mg once daily for 6 weeks)
Number of subjects: 39
Study 16644608 — intervention group
Group type: EXPERIMENTAL
Intervention: bimatoprost 0.03%
Number of subjects: 50
Study 16644608 — intervention group
Group type: COMPARATOR
Intervention: timolol-latanoprost combination
Number of subjects: 50
Study 12588678 — intervention group
Group type: EXPERIMENTAL
Intervention: Spend Less. Eat Well. Feel Better. (SLEWFB) program
Number of subjects: 95
Study 12588678 — intervention group
Group type: COMPARATOR
Intervention: 1-hour food safety intervention
Number of subjects: 95
Study 11114263 — intervention group
Group type: EXPERIMENTAL
Intervention: Ataxia-telangiectasia (AT) patients
Number of subjects: 0
Study 11114263 — intervention group
Group type: EXPERIMENTAL
Intervention: Charcot-Marie-Tooth 1A (CMT-1A) patients
Number of subjects: 0
Study 11114263 — intervention group
Group type: COMPARATOR
Intervention: Neurotoxin-induced motor discoordination model
Number of subjects: 0
Study 11114263 — intervention group
Group type: COMPARATOR
Intervention: Diabetic neuropathy model
Number of subjects: 0
Study 11114263 — intervention group
Group type: COMPARATOR
Intervention: Hereditary cerebellar ataxia model
Number of subjects: 0
Study 8651712 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 122
Study 1510736 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (9 kV/m, 20 microT)
Number of subjects: 30
Study 1510736 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (9 kV/m, 20 microT)
Number of subjects: 30
Study 6192155 — intervention group
Group type: EXPERIMENTAL
Intervention: gingivectomy
Number of subjects: 6
Study 6192155 — intervention group
Group type: EXPERIMENTAL
Intervention: flap‐excision
Number of subjects: 6
Study 6192155 — intervention group
Group type: EXPERIMENTAL
Intervention: gingivectomy and flap‐excision
Number of subjects: 6
Study 29866467 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (solifenacin succinate 5mg plus mirabegron 50mg)
Number of subjects: 1794
Study 29866467 — intervention group
Group type: COMPARATOR
Intervention: Mirabegron 50mg
Number of subjects: 1794
Study 29866467 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin 5mg
Number of subjects: 1794
Study 27227679 — intervention group
Group type: EXPERIMENTAL
Intervention: PrePex device
Number of subjects: 240
Study 27227679 — intervention group
Group type: COMPARATOR
Intervention: Forceps-guided surgical circumcision
Number of subjects: 240
Study 24848282 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with RA and proteinuria
Number of subjects: 42
Study 24848282 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy blood donors)
Number of subjects: 42
Study 24848282 — intervention group
Group type: COMPARATOR
Intervention: RA patients without proteinuria
Number of subjects: 42
Study 24848282 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with glomerulonephritis
Number of subjects: 42
Study 24848282 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with AA-amyloidosis
Number of subjects: 42
Study 24848282 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with tubulointerstitial nephritis
Number of subjects: 42
Study 22891946 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein A-IV (apoA-IV) concentration
Number of subjects: 1255
Study 22891946 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein A-IV (apoA-IV) concentration in patients with BMI > 23 kg m(‐2)
Number of subjects: 1255
Study 22891946 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein A-IV (apoA-IV) concentration in nonwasting group
Number of subjects: 1255
Study 20164553 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency field exposure (890-MHz GSM signal, specific absorption rate of 1.0 Watt/kg) for 30 minutes
Number of subjects: 313
Study 20164553 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of oral snuff
Number of subjects: 313
Study 20164553 — intervention group
Group type: EXPERIMENTAL
Intervention: Time since first use of mobile phones and desktop cordless phones combined
Number of subjects: 313
Study 17662037 — intervention group
Group type: EXPERIMENTAL
Intervention: Active immunotherapy with Alternaria alternata extract
Number of subjects: 28
Study 17662037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 16209678 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubricated endoscope
Number of subjects: 150
Study 16209678 — intervention group
Group type: COMPARATOR
Intervention: Unlubricated endoscope
Number of subjects: 150
Study 15189613 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagining oneself in the other's place
Number of subjects: 0
Study 15189613 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagining the other's feelings
Number of subjects: 0
Study 11868841 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental liquid dentifrice containing 0.3% triclosan, 2.0% PVM/MA copolymer, and 0.243% sodium fluoride
Number of subjects: 0
Study 11868841 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice containing 0.243% sodium fluoride
Number of subjects: 0
Study 10561949 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg plus dexamethasone 8 mg i.v. on day 1 followed by tropisetron 5 mg p.o. plus dexamethasone 4 mg orally bid on day 2‐6 (group I)
Number of subjects: 30
Study 10561949 — intervention group
Group type: COMPARATOR
Intervention: Tropisetron 5 mg p.o. alone on day 2‐6 (group II)
Number of subjects: 30
Study 8778152 — intervention group
Group type: EXPERIMENTAL
Intervention: plain Synacthen, 250 micrograms, iv
Number of subjects: 20
Study 8778152 — intervention group
Group type: COMPARATOR
Intervention: depot Synacthen, 1000 micrograms, im
Number of subjects: 20
Study 2225517 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrode A (gastric antrum)
Number of subjects: 5
Study 2225517 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrode B (gastric body)
Number of subjects: 5
Study 2225517 — intervention group
Group type: COMPARATOR
Intervention: Aspiration
Number of subjects: 5
Study 2225517 — intervention group
Group type: EXPERIMENTAL
Intervention: Both electrodes
Number of subjects: 5
Study 7461012 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiamenidine (HOE 440)
Number of subjects: 10
Study 7461012 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after withdrawal of Tiamenidine)
Number of subjects: 10
Study 31744796 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord blood serum (CBS) eyedrops administered eight times/day for 1 month
Number of subjects: 60
Study 31744796 — intervention group
Group type: COMPARATOR
Intervention: Peripheral adult donor blood serum (PBS) eyedrops administered eight times/day for 1 month
Number of subjects: 60
Study 31744796 — intervention group
Group type: EXPERIMENTAL
Intervention: CBS treatment
Number of subjects: 60
Study 31744796 — intervention group
Group type: COMPARATOR
Intervention: PBS treatment
Number of subjects: 60
Study 31154814 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 0
Study 31154814 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational studies and small interventional studies
Number of subjects: 0
Study 31154814 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic recommendations
Number of subjects: 0
Study 28593244 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandarin orange yogurt for 2 weeks
Number of subjects: 57
Study 28593244 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandarin orange yogurt
Number of subjects: 57
Study 28593244 — intervention group
Group type: COMPARATOR
Intervention: Control yogurt (lacking mandarin orange)
Number of subjects: 57
Study 26001320 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular (EVAR)
Number of subjects: 107
Study 26001320 — intervention group
Group type: COMPARATOR
Intervention: Open Surgical Repair (OSR)
Number of subjects: 107
Study 24219189 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor learning program (goal-oriented stepping and walking, strength training, twice weekly for 1 hour for 12 weeks)
Number of subjects: 40
Study 24219189 — intervention group
Group type: COMPARATOR
Intervention: Standard exercise program (endurance training by treadmill walking, strength training, twice weekly for 1 hour for 12 weeks)
Number of subjects: 40
Study 24219189 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Motor learning and Standard)
Number of subjects: 40
Study 21209239 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib (R788) 100 mg orally, twice daily from days 4 to 8 and once daily on days 3 and 9.
Number of subjects: 16
Study 21209239 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo, twice daily from days 4 to 8 and once daily on days 3 and 9.
Number of subjects: 16
Study 19064372 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping self-efficacy
Number of subjects: 3670
Study 19064372 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive depression
Number of subjects: 3670
Study 19064372 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom intrusiveness
Number of subjects: 3670
Study 17598695 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone dihydrogen phosphate disodium salt (test product)
Number of subjects: 210
Study 17598695 — intervention group
Group type: COMPARATOR
Intervention: Comparator product (control)
Number of subjects: 210
Study 15039645 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional laparoscopy under GA
Number of subjects: 24
Study 15039645 — intervention group
Group type: EXPERIMENTAL
Intervention: Gasless laparoscopy under GA
Number of subjects: 24
Study 15039645 — intervention group
Group type: EXPERIMENTAL
Intervention: Gasless laparoscopy under epidural anesthesia
Number of subjects: 24
Study 11533360 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive home visiting program
Number of subjects: 225
Study 9462459 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective attention to grating orientation
Number of subjects: 0
Study 9462459 — intervention group
Group type: COMPARATOR
Intervention: Control task involving selective attention to grating dimensions
Number of subjects: 0
Study 7939398 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (5 mg four times daily)
Number of subjects: 137
Study 7939398 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (200 mg four times daily)
Number of subjects: 137
Study 7939398 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 137
Study 7939398 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 137
Study 2896104 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride 4.4 mg
Number of subjects: 10
Study 2896104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29254749 — intervention group
Group type: EXPERIMENTAL
Intervention: Water intake (GII)
Number of subjects: 325
Study 29254749 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydrating fluids (GIII)
Number of subjects: 325
Study 29254749 — intervention group
Group type: COMPARATOR
Intervention: No fluid intake (GI)
Number of subjects: 325
Study 29254749 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between GII and GIII
Number of subjects: 325
Study 26866954 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) or emtricitabine/TDF
Number of subjects: 518
Study 26866954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 518
Study 24366750 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg oseltamivir
Number of subjects: 24
Study 24366750 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg oseltamivir
Number of subjects: 24
Study 24366750 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of oseltamivir (75 mg and 150 mg)
Number of subjects: 24
Study 24366750 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dosing of oseltamivir
Number of subjects: 24
Study 22790902 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo vaginal ring worn for 12 weeks
Number of subjects: 170
Study 20660039 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative TSH suppression therapy (group A) with L-T(4) to keep serum TSH levels below 0.01 μU/ml
Number of subjects: 433
Study 20660039 — intervention group
Group type: COMPARATOR
Intervention: No TSH suppression (group B) with TSH levels adjusted to within normal ranges
Number of subjects: 433
Study 18771362 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous bone grafting plus calcium sulfate
Number of subjects: 12
Study 18771362 — intervention group
Group type: COMPARATOR
Intervention: Autogenous bone grafting with a bioabsorbable membrane
Number of subjects: 12
Study 16199249 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg/d for 5 days
Number of subjects: 177
Study 16199249 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin 500 mg/d for 10 days
Number of subjects: 177
Study 16199249 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 177
Study 15032259 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg bupropion SR daily and PTC
Number of subjects: 1524
Study 15032259 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg bupropion SR daily and TM
Number of subjects: 1524
Study 15032259 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg bupropion SR daily and PTC
Number of subjects: 1524
Study 15032259 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg bupropion SR daily and TM
Number of subjects: 1524
Study 15032259 — intervention group
Group type: COMPARATOR
Intervention: 150 mg bupropion SR
Number of subjects: 1524
Study 15032259 — intervention group
Group type: COMPARATOR
Intervention: 300 mg bupropion SR
Number of subjects: 1524
Study 11054442 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (1 g every 8 hours)
Number of subjects: 411
Study 11054442 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime (2 g every 8 hours)
Number of subjects: 411
Study 8818068 — intervention group
Group type: EXPERIMENTAL
Intervention: CATCH family intervention with varying levels of adult participation (measured by the number of activity packets completed)
Number of subjects: 0
Study 8818068 — intervention group
Group type: EXPERIMENTAL
Intervention: CATCH family intervention
Number of subjects: 0
Study 1577054 — intervention group
Group type: EXPERIMENTAL
Intervention: DuP-753 25 mg
Number of subjects: 21
Study 1577054 — intervention group
Group type: EXPERIMENTAL
Intervention: DuP-753 50 mg
Number of subjects: 21
Study 1577054 — intervention group
Group type: EXPERIMENTAL
Intervention: DuP-753 100 mg
Number of subjects: 21
Study 1577054 — intervention group
Group type: EXPERIMENTAL
Intervention: DuP-753 200 mg
Number of subjects: 21